ATX inhibitor 5|cas:2402772-45-4|西域试剂

ATX inhibitor 5,99.77%

产品编号：Bellancom-133019| CAS NO：2402772-45-4| 分子式：C₂₂H₁₈ClF₃N₆O| 分子量：474.87

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-133019	￥3500.00	杭州北京（现货）
Bellancom-133019	￥5800.00	杭州北京（现货）
Bellancom-133019	￥11000.00	杭州北京（现货）
Bellancom-133019	￥17000.00	杭州北京（现货）
Bellancom-133019	￥25000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

ATX inhibitor 5

产品介绍

ATX inhibitor 5 是有效的口服活性 autotaxin (ATX) 抑制剂，IC₅₀ 为 15.3 nM。AATX inhibitor 5 具有抗肝纤维化作用，并显着降低 CCl4 诱导的肝纤维化水平。

生物活性

ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor, with an IC₅₀ of 15.3 nM. ATX inhibitor 5 shows anti-hepatofibrosis effects and reduces CCl4-induced hepatic fibrosis level prominently.

体外研究

ATX inhibitor 5 (compound 10g) (IC₅₀s=1.21 and 0.78 μM) displays activities against cardiac fibroblasts (CFs) and hepatic stellate cell (HSC).
ATX inhibitor 5 at 10 μM successfully suppresses collagen content induced by TGF-β.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	CFs and t-HSC/Cl-6 cells
Concentration:	0.0001, 0.01, 1, 100, 10000 µM
Incubation Time:	48 hours
Result:	Displayed activities against CFs and t-HSC/Cl-6 cells with IC₅₀s of 1.21 and 0.78 µM, respectively.

体内研究
(In Vivo)

ATX inhibitor 5 (20-40 mg/kg; p.o.; once daily for two weeks) reduces CCl4-induced hepatic fibrosis level prominently.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Konmin mice (8-week old, 22-25 g)
Dosage:	20, 40 mg/kg
Administration:	Orally; once daily for two weeks
Result:	Prominently reduced CCl4-induced hepatic fibrosis level.

体内研究

ATX inhibitor 5 (20-40 mg/kg; p.o.; once daily for two weeks) reduces CCl4-induced hepatic fibrosis level prominently.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Konmin mice (8-week old, 22-25 g)
Dosage:	20, 40 mg/kg
Administration:	Orally; once daily for two weeks
Result:	Prominently reduced CCl4-induced hepatic fibrosis level.

体内研究

ATX inhibitor 5 (20-40 mg/kg; p.o.; once daily for two weeks) reduces CCl4-induced hepatic fibrosis level prominently.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Konmin mice (8-week old, 22-25 g)
Dosage:	20, 40 mg/kg
Administration:	Orally; once daily for two weeks
Result:	Prominently reduced CCl4-induced hepatic fibrosis level.

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (526.46 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1058 mL	10.5292 mL	21.0584 mL
5 mM	0.4212 mL	2.1058 mL	4.2117 mL
10 mM	0.2106 mL	1.0529 mL	2.1058 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.38 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.38 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。